U.S. reps call for PBM merger probe; Allergan wins Lumigan patent dispute;

@FiercePharma: 15% growth in Provenge sales won't cut it for Dendreon, so 500 staffers will get the axe. News | Follow @FiercePharma

> Three Democratic congressional representatives are asking regulators to scrutinize the proposed $29.1 billion merger between Express Scripts and Medco Health Solutions, citing worries about higher drug costs for consumers. Report

> Allergan's ($AGN) patent on the eye drug Lumigan is valid, a court has ruled; therefore, generic versions from Teva Pharmaceutical Industries ($TEVA) and Novartis' ($NVS) Sandoz unit infringed it. Article

> The cost of shutting down AIDS transmission significantly would be $6 billion, a tough figure to support in a slumping economy. Report

> Merck Serono is shopping for a public relations agency to work on its cancer drug Erbitux, an account currently said to be held by Chandler Chicco Agency. Story

> GlaxoSmithKline ($GSK) has inked a deal to provide 400 million more tablets each year of a drug to fight intestinal worms in children to the World Health Organization. Release

> AstraZeneca ($AZN) has bought another 800,000 of its own shares for cancellation at 2821 pence per share. More

> The Medicines Co. ($MDCO) launched a 50-ml ready-to-use version of its Argatroban injection, a direct thrombin inhibitor and anticoagulant. Release

> Indian officials have opened Goa's Mormugao port to pharma exports beginning next month. The move saves Goa manufacturers the cost of shipping their products to the Mumbai port they previously had to use. Item

Biotech News

@FierceBiotech: Study aims decode baby DNA, create analysis tools. Story | Follow @FierceBiotech

@JohnCFierce: And now for something completely different. Russian agency backs upstart nano-bio with tailored pricing plan. Item | Follow @JohnCFierce

@RyanMFierce: @LifeSciVC (Bruce Booth) analyzes our shrinking biotech eco system, 27% drop in biopharmas over past 5 years. Article | Follow @RyanMFierce

@MaureenFierce: FDA lifts hold on RXi breast cancer vaccine trial. News | Follow @MaureenFierce

> Gilead faces high hopes for "Quad" as it hatches big expansion plan. Piece

> Russian agency backs upstart nano-bio with tailored pricing plan. Item

Biotech IT News

> Study aims decode baby DNA, create analysis tools. Article

> Scientists explore new model in battle against kidney disease. Report

> CLC bio building bioinformatics foundation for $4M cancer project. More

> U.K. groups building genomic cloud. Story

> Microsoft video-game tech used to detect illness. More

Medical Device News

> Valeritas completes $150M Series C round. News

> Masimo hit with patent lawsuit. Piece

> Cochlear shares take a dive on news of recall. Report

> Panel mulls tougher rules for transvaginal meshes. Item

And Finally... The middle class has to be declining if Procter & Gamble ($PG) thinks so. Report

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.